{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.19","upperLimit":"0.5","value":"0.31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma","id":"OG000","title":"Relapsed Multiple Myeloma"},{"description":"This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma.","id":"OG001","title":"High-risk Multiple Myeloma"}],"paramType":"NUMBER","populationDescription":"This objective only applies to Arm I: Participants with Relapsed Multiple Myeloma","reportingStatus":"POSTED","timeFrame":"2 years","title":"Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS)","type":"PRIMARY","unitOfMeasure":"Proportion of participants PFS"}